Drug Trial Radar · NCT00113269
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
Last checked: Nov 20, 2026Latest source record: Aug 11, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
501
Actual
Start
May 2005
Primary completion
Mar 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and efficacy of different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal transplant recipients treated with tacrolimus, mycophenolate mofetil (MMF) and a rapid steroid withdrawal.
Conditions
- Kidney Transplantation
Interventions
basiliximabDrug
IV
rabbit anti-thymocyte globulinDrug
IV
tacrolimusDrug
oral
alemtuzumabDrug
Intravenous (IV)
mycophenolate mofetilDrug
oral
steroidsDrug
IV and/or oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient Incidence of Biopsy-confirmed Acute Rejection (BCAR) at 6 MonthsTime frame: 6 months
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Los Angeles, California
Site not named
Palo Alto, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
San Francisco, California
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Washington D.C., District of Columbia
Site not named
Miami, Florida
Site not named
Tampa, Florida
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Livingston, New Jersey
Site not named
New Brunswick, New Jersey
Site not named
Hawthorne, New York
Site not named
New York, New York
Site not named
New York, New York
Site not named
Chapel Hill, North Carolina
Site not named
Durham, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Portland, Oregon
Site not named
Danville, Pennsylvania
Site not named
Harrisburg, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
San Antonio, Texas
Site not named
Salt Lake City, Utah
Site not named
Madison, Wisconsin
Site not named
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.